What question did this study set out to answer?

Assess the efficacy and safety of neoadjuvant immune checkpoint inhibitor monotherapy in reducing recurrence rates and mortality following surgical resection for hepatocellular carcinoma.

March 6, 2025npj Precision OncologyOpen Access

Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

View Full Paper

Ask AI

Bookmark

Assess the efficacy and safety of neoadjuvant immune checkpoint inhibitor monotherapy in reducing recurrence rates and mortality following surgical resection for hepatocellular carcinoma.
Synthesized evidence from clinical trials evaluating immune checkpoint inhibitor (ICI) monotherapy administered prior to surgical resection in hepatocellular carcinoma.
Neoadjuvant immune checkpoint inhibitors achieved complete and partial tumor responses prior to planned surgical resection.
Clinical trials demonstrated favorable safety profiles and reductions in post-surgical recurrence rates and overall mortality.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical review demonstrates reduced recurrence and mortality with neoadjuvant immune checkpoint inhibitors in hepatocellular carcinoma, indicating improved surgical outcomes.

Cite This Study

Akula et al. (2025) studied this question.

synapsesocial.com/papers/6a78a837576efb0ddaf83b0e https://doi.org/10.1038/s41698-025-00846-4

View Full Paper

Ask AI

Bookmark

Implication

Clinical review demonstrates reduced recurrence and mortality with neoadjuvant immune checkpoint inhibitors in hepatocellular carcinoma, indicating improved surgical outcomes.

Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

Key Points

Discussion

Implication

Cite This Study

Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider